Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes

Internal Medicine

Volumn 47, Issue 13, 2008, Pages 1181-1188

  Kawai, Toshihide ^a   Funae, Osamu ^b   Shimada, Akira ^a   Tabata, Mitsuhisa ^a   Hirata, Takumi ^a   Atsumi, Yoshihito ^b   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

Atherogenic index of plasma (AIP); Combination therapy; Metformin; Pioglitazone; Weight gain

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID;

ADULT; ARTICLE; ATHEROGENESIS; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LEG EDEMA; LIPID METABOLISM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; WEIGHT GAIN; AGED; BLOOD; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; JAPAN; METABOLISM; MIDDLE AGED;

AGED; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIPIDS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 49649103582     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0969     Document Type: Article

References (32)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431, 1998.
2. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type diabetes in Asia. Lancet 369: 1681-1688, 2006.
3. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991.
4. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N Engl J Med 338: 867-872, 1998.
5. Stumvoll M, Nurjhan N, Perriello, G, Dailey G, Gerich JE. Metabolic, effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 333: 550-554, 1995.
6. Bailey CJ, Path MRC, Turner RC. Drug therapy: Metformin. N Engl J Med 334: 574-579, 1996.
7. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 6: 89-131, 1998.
8. Yki-Jarvinen H. Drug therapy: thiazolidinediones. N Engl J Med 351: 1106-1118, 2004.
9. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. Pioglitazone 026 study' group: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 12: 413-423, 2001.
10. Schernthaner G, Matthews D, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double blind, randomized trial. J Clin Endocrinol Metab 89, 6068-6076, 2004.
11. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; on behalf of the QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a: sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27: 141-147, 2004.
12. Kawai T, Takei I, Oguma Y, et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48: 1102-1107, 1999.
13. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51: 314-317, 2002.
14. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88: 1637-1645, 2003.
15. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6: 133-156, 2004.
16. National Cholesterol Education Program: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult_Treatment Panel III). JAMA 285: 2486-2497, 2005.
17. HDL). Clin Biochem 34: 583-388, 2001.
18. Dobiásová M. Atherogenic index of plasma [Log(Triglycerides/HDL-Cholesterol)]: Theoretical and practical implications. Clin Chem 50: 1113-1115, 2004.
19. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma tnglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34: 1687-1697, 1993.
20. Mowat BF, Skinner ER, Wilson HM, Leng GC, Fowkes FG, Horrobin D. Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease. Atherosclerosis 131: 161-166, 1997.
21. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 50: 1184-1188, 2004.
22. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative stddy. Diabetes Metabol Res Rev 21: 167-174, 2005.
23. Betteridge DJ, Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in tile teatment of type 2 diabetes. Diabetologia 48: 2477-2481, 2005.
24. Dormandy JA, Charbonnel B, Eckland DA, et al; on behalf of the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366: 1279-1289, 2005.
25. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 355: 2477-2480, 2006.
26. Chen L, Yang B, McNulty JA, et al. GI262570, a peroxisome proliferator-activated receptor γ agonist, change electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther 312: 718-725, 2005.
27. Staels B. Fluid retention mediated by renal PPARγ. Cell Metabolism 2: 77-78, 2005.
28. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101: 1354-1361, 1998.
29. Majima T, Komatsu Y, Doi K, et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J 53: 325-330, 2006.
30. Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27: 1577-1583, 2004.
31. Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cbolesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 29: 1016-1023, 2006.
32. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103: 491-497, 1997.